Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MPWE...80% gain in the last couple of days...MACD positive at bottoms, trend line broke...MA's are converging...nice entry point:)
Trader412,
Didn't mean to reply to you personally...was just thinking out loud on the board. I have a good penny in this as well, and from the looks of the company...management seems up front. Crooks don't go to the bank they just robbed and open up an account. At least smart ones don't. That is, IMO of course.
Seabring, that is your opinion. My charting skills haven't failed much, and yes I am a flipper, but also a core holder. I went in to BHUB based on its chart, and yes, I am here holding the bag as well. That is the name of the game down here.
It is a mere waste of my breath and nerves to complain till I am blue in the face over what happened, too much stress.
Chart looks great...got in yesterday at .0007.
yes, but the SEC did not suspend trading BHUB
bhub's halt will be lifted and this stock will soar.
The graph tells me just that. I invested in this company solely based on the oblong and angled cup and handle patterns that had formed in the last mon. Two so far and rearing up for another leg up.
The only question here is, how far north and will it gap up?
I go for the latter.
Life really is too short.
that flock together..:).....bhub's halt will be lifted and this stock will soar.
The graph tells me just that. I invested in this company solely based on the oblong and angled cup and handle patterns that had formed in the last mon. Two so far and rearing up for another leg up.
The only question here is, how far north and will it gap up?
I go for the latter.
Life really is too short.
Not worried either...just looking at the graph....don't we see a pattern happening here?
I liike what I see.
http://www.timesonline.co.uk/tol/life_and_style/health/article1637528.ece
April 11, 2007
Diabetics cured by stem-cell treatment
David Rose
Diabetics using stem-cell therapy have been able to stop taking insulin injections for the first time, after their bodies started to produce the hormone naturally again.
In a breakthrough trial, 15 young patients with newly diagnosed type 1 diabetes were given drugs to suppress their immune systems followed by transfusions of stem cells drawn from their own blood.
The results show that insulin-dependent diabetics can be freed from reliance on needles by an injection of their own stem cells. The therapy could signal a revolution in the treatment of the condition, which affects more than 300,000 Britons.
People with type 1 diabetes have to give themselves regular injections to control blood-sugar levels, as their ability to create the hormone naturally is destroyed by an immune disorder.
Related Links
Condition is ideal target for this kind of transplantation
Stem Tide
British scientists grow part of human heart
All but two of the volunteers in the trial, details of which are published today in the Journal of the American Medical Association (JAMA), do not need daily insulin injections up to three years after stopping their treatment regimes.
The findings were released to reporters yesterday as the future of US stem-cell research was being debated in Washington.
Stem cells are immature, unprogrammed cells that have the ability to grow into different kinds of tissue and can be sourced from people of all ages.
Previous studies have suggested that stem-cell therapies offer huge potential to treat a variety of diseases such as Alzheimer’s, Parkinson’s and motor neuron disease. A study by British scientists in November also reported that stem-cell injections could repair organ damage in heart attack victims.
But research using the most versatile kind of stem cells — those acquired from human embryos — is currently opposed by powerful critics, including President Bush.
The JAMA study provides the first clinical evidence for the efficacy of stem cells in type 1 diabetes. Sufferers of the chronic condition, which normally emerges in childhood or early adulthood, have to inject themselves at least four times a day.
Type 2 diabetes, which tends to affect people later in life, is linked to lifestyle factors such as obesity. There are almost two million type 2 diabetics in Briton, most of whom control their blood-sugar levels with pills or through diet.
The new study, by a joint team of Brazilian and American scientists, found that one of the first patients to undergo the procedure has not used any supplemental synthetic
insulin for three years. “Very encouraging results were obtained in a small number of patients with early-onset disease,” the authors, led by Julio Voltarelli, from the University of São Paulo in Ribeirão Preto, Brazil. write. “Ninety-three per cent of patients achieved different periods of insulin independence and treatment-related toxicity was low, with no mortality.”
Type 1 diabetes occurs when the body’s own immune system malfunctions and destroys the insulin-producing beta cells of the pancreas, causing a shortage in the hormone.
By the time most patients receive a clinical diagnosis, 60 to 80 per cent of their beta cells have been wiped out. The disease progresses from this point very quickly, and can result in serious long-term complications including blindness, kidney failure, heart disease and stroke.
Dr Voltarelli’s team hoped that if they intervened early enough they could wipe out and then rebuild the body’s immune system by using stem cells, preverving a reservoir of beta cells and allowing them to to regenerate.
They enrolled Brazilian diabetics aged between 14 and 31 who had been diagnosed within the previous six weeks. After stem cells had been harvested from their blood, they then underwent a mild form of chemotherapy to eliminate the white blood cells causing damage to the pancreas. They were then given transfusions of their own stem cells to help rebuild their immune systems.
Richard Burt, a co-author of the study from Northwestern University’s Feinberg School of Medicine in Chicago, said that 14 of the 15 patients were insulin-free for some time following the treatment. Eleven of those were able to dispense with supplemental insulin immediately following the infusion of stem cells and have not had recourse to synthetic insulin since then, he said.
“Two other patients needed some supplemental insulin for 12 and 20 months after the procedure, but eventually both were able to wean themselves from taking daily shots,” he added. One patient went 12 months without shots, but relapsed a year after treatment after suffering a viral infection, and resumed daily insulin injections. Another volunteer was eliminated from the study because of complications. The therapy, known as autologous hematopoietic stem cell transplantation, has already shown benefits to individuals with a range of auto-immune diseases such as rheumatoid arthritis, Crohn’s disease and lupus.
There are still question marks about exactly how the treatment works, and further studies will be required to fully evaluate it’s safety and efficacy.
“As a research scientist I am always hesitant to speak of a cure, but the initial results have been good and show the importance of conducting more trials,” Dr Burt said.
Given the right funding opportunities, university hospitals in London could be conducting research into the therapy within the next 12 months, he added.
“It will probably be five to eight years before we see a treatment being widely available,” he said.
In an accompanying editorial in JAMA, Dr Jay Skyler, of the Diabetes Research Institute at the University of Miami, wrote: “Research in this field is likely to explode in the next few years and should include randomised controlled trials, as well as mechanistic studies."
http://www.timesonline.co.uk/tol/life_and_style/health/article1637528.ece
11, 2007
Diabetics cured by stem-cell treatment
David Rose
Diabetics using stem-cell therapy have been able to stop taking insulin injections for the first time, after their bodies started to produce the hormone naturally again.
In a breakthrough trial, 15 young patients with newly diagnosed type 1 diabetes were given drugs to suppress their immune systems followed by transfusions of stem cells drawn from their own blood.
The results show that insulin-dependent diabetics can be freed from reliance on needles by an injection of their own stem cells. The therapy could signal a revolution in the treatment of the condition, which affects more than 300,000 Britons.
People with type 1 diabetes have to give themselves regular injections to control blood-sugar levels, as their ability to create the hormone naturally is destroyed by an immune disorder.
Related Links
Condition is ideal target for this kind of transplantation
Stem Tide
British scientists grow part of human heart
All but two of the volunteers in the trial, details of which are published today in the Journal of the American Medical Association (JAMA), do not need daily insulin injections up to three years after stopping their treatment regimes.
The findings were released to reporters yesterday as the future of US stem-cell research was being debated in Washington.
Stem cells are immature, unprogrammed cells that have the ability to grow into different kinds of tissue and can be sourced from people of all ages.
Previous studies have suggested that stem-cell therapies offer huge potential to treat a variety of diseases such as Alzheimer’s, Parkinson’s and motor neuron disease. A study by British scientists in November also reported that stem-cell injections could repair organ damage in heart attack victims.
But research using the most versatile kind of stem cells — those acquired from human embryos — is currently opposed by powerful critics, including President Bush.
The JAMA study provides the first clinical evidence for the efficacy of stem cells in type 1 diabetes. Sufferers of the chronic condition, which normally emerges in childhood or early adulthood, have to inject themselves at least four times a day.
Type 2 diabetes, which tends to affect people later in life, is linked to lifestyle factors such as obesity. There are almost two million type 2 diabetics in Briton, most of whom control their blood-sugar levels with pills or through diet.
The new study, by a joint team of Brazilian and American scientists, found that one of the first patients to undergo the procedure has not used any supplemental synthetic
insulin for three years. “Very encouraging results were obtained in a small number of patients with early-onset disease,” the authors, led by Julio Voltarelli, from the University of São Paulo in Ribeirão Preto, Brazil. write. “Ninety-three per cent of patients achieved different periods of insulin independence and treatment-related toxicity was low, with no mortality.”
Type 1 diabetes occurs when the body’s own immune system malfunctions and destroys the insulin-producing beta cells of the pancreas, causing a shortage in the hormone.
By the time most patients receive a clinical diagnosis, 60 to 80 per cent of their beta cells have been wiped out. The disease progresses from this point very quickly, and can result in serious long-term complications including blindness, kidney failure, heart disease and stroke.
Dr Voltarelli’s team hoped that if they intervened early enough they could wipe out and then rebuild the body’s immune system by using stem cells, preverving a reservoir of beta cells and allowing them to to regenerate.
They enrolled Brazilian diabetics aged between 14 and 31 who had been diagnosed within the previous six weeks. After stem cells had been harvested from their blood, they then underwent a mild form of chemotherapy to eliminate the white blood cells causing damage to the pancreas. They were then given transfusions of their own stem cells to help rebuild their immune systems.
Richard Burt, a co-author of the study from Northwestern University’s Feinberg School of Medicine in Chicago, said that 14 of the 15 patients were insulin-free for some time following the treatment. Eleven of those were able to dispense with supplemental insulin immediately following the infusion of stem cells and have not had recourse to synthetic insulin since then, he said.
“Two other patients needed some supplemental insulin for 12 and 20 months after the procedure, but eventually both were able to wean themselves from taking daily shots,” he added. One patient went 12 months without shots, but relapsed a year after treatment after suffering a viral infection, and resumed daily insulin injections. Another volunteer was eliminated from the study because of complications. The therapy, known as autologous hematopoietic stem cell transplantation, has already shown benefits to individuals with a range of auto-immune diseases such as rheumatoid arthritis, Crohn’s disease and lupus.
There are still question marks about exactly how the treatment works, and further studies will be required to fully evaluate it’s safety and efficacy.
“As a research scientist I am always hesitant to speak of a cure, but the initial results have been good and show the importance of conducting more trials,” Dr Burt said.
Given the right funding opportunities, university hospitals in London could be conducting research into the therapy within the next 12 months, he added.
“It will probably be five to eight years before we see a treatment being widely available,” he said.
In an accompanying editorial in JAMA, Dr Jay Skyler, of the Diabetes Research Institute at the University of Miami, wrote: “Research in this field is likely to explode in the next few years and should include randomised controlled trials, as well as mechanistic studies."
you can sell on TD..just can't buy.
TDAMER has restricted buying on this...only selling...What this tells me...it is going to pop!
Now that doesn't seem like him at all. Nice try, but to no avail.
They just don't have the all seeing eye that some of us do, and are able to predict the coming storm. we stopped today at the 1st resistance level of .007...good day.
With forms coming out in the next 24 hrs, it is all too clear there is more steam.
I am able to pull up L2 for the OTCBB on my Ameritrade, just not the pinks. Can you not pull up OB securities?
read this message if you want to know anything about me, otherwise keep your bashing and pumping replies (from what I have seen in your posts...stop chasing stocks!) to yourself, or at least off my inbox.
http://www.investorshub.com/boards/read_msg.asp?message_id=17663793
FYI: Always follow your Moving Averages, not the CEO. Take your profits when they come. However, it is a diamond in the rough when companies are transparent, especially in pennyland...as INXR is.
I know everyone here is getting nervous, but to recap on the company and their goals to help us hold just a little bit longer.
BTW, what the heck is going on with PLYCF?
iFinix Corporation Discusses Company Agenda for 2007
iFinix Corp. Jamaica, New York (Other OTC: INXR.PK- News) released today a comprehensive overview of iFinix's corporate strategy and goals for 2007. Chairman Drew Budhu commented, "As iFinix embarks on an accelerated entry into the financial marketplace with its comprehensive line of real time and trading platforms, the level of inquiry from prospective users of our products, shareholders and potential investors has increased dramatically. The following summary will prepare our clients for their future with iFinix and address shareholder concerns at this opportune turning point in our corporate history."
Core Objectives
iFinix CEO Doug Spadaro stated, "iFinix's objectives are three-fold. We will deliver quality real time trading tools and execution platforms to the financial marketplace at a competitive price, effectively support our subscribers and eliminate any obstacles that limit achieving solid returns for our shareholders. We consider these objectives to be more than mere goals. They are our obligations to the consumers and shareholders who support us and whom we work for."
iFinix Financial Products
The iFinix product suite will initially consist of three products. After conducting extensive market research, the company will rebrand their product suite along the following lines:
iFinix RealTime is the desktop real time platform being prepared for release. The modular components offered include Streaming Quotes with unlimited ticker lists, Level 2, Time & Sales, Alerts, Charting, Streaming News, Financial Content and Market Research.
iFinix RealTime will also be upgraded soon after release to include stock screens and real time scanners with fully configurable market motion filters. iFinix will be including these added functions at no extra cost to provide a superior value and competitive product.
iFinix Trader will add trade execution functionality and account management features to the iFinix RealTime platform. iFinix Trader will integrate with partnered broker-dealers thus affording iFinix users high speed trade executions at a range of brokerages. iFinix Trader will be made available both to retail traders and professional organizations.
With iFinix RealTime rolling out first, iFinix Trader will go to market release as new brokerage partnerships are announced. Users will be able to trade and manage multiple iFinix-partner brokerage accounts aggregated within a single iFinix Trader environment. With the ability to hook into an assortment of high-speed direct access brokers, iFinix will continue to expand your trading choices as each new broker joins our network.
Efinix is a web enabled version of iFinix Trader that will run on desktops and on mobile devices. With Efinix, you will be able to track the markets, manage your portfolio and trade online using the same execution features as iFinix Trader. Efinix is in advanced stages of development and being prepared for release.
Product Strategy
iFinix's business model is subscription based for iFinix RealTime and Efinix. Users that trade through a participating brokerage will receive iFinix Trader on a low or no cost basis. iFinix will receive a percentage of each commission fee from trades executed using iFinix Trader.
Due to the large range of brokerage services and tools investors employ, this diversified business model ensures iFinix products will be available in all contexts and the company will generate an income under all scenarios.
iFinix will offer various subscription pricing tiers for essential platform services plus add-on services and extra exchanges at a cost less than the basic and total package prices of other vendors with comparable offerings.
As market penetration of the iFinix platforms increase, communications protocols for other programmers will be made available to encourage the building of product add-ons. The company will partner with these developers and assist in the marketing of these value-added products.
All iFinix product is coded by iFinix.Earlier iFinix product demos are no longer active or to be considered representative of market-ready products soon to be released. Free product trial subscriptions will be offered when each product is released.
Product Support
When iFinix RealTime is officially released, live technical support will be provided via chat messaging on the iFinix website and by email on weekdays from 8 a.m. - 6 a.m. EST. The company guarantees weekend support requests will be resolved by Monday market open.
Live support hours may be expanded later as the user base expands. Chairman Drew Budhu will go to India soon to review current development efforts and to finalize the training of tech support staff, initiate support tracking procedures and establish knowledge base protocols.
Management
iFinix was founded by Drew Budhu, a specialist in distributed computing environments. Mr. Budhu is the chief architect of iFinix products and technology initiatives
Mr. Budhu comments, "I have held fast to my vision of making iFinix a value-added proposition for both the consumer marketplace and our shareholders. I worked hard to keep our company going until we reached the threshold of delivering product to the marketplace and we are finally on our way. We have no debt, take marginal salaries, keep our costs lean and are determined to grow the company in 2007."
CEO Doug Spadaro has held management positions at Citicorp, ABN/AMRO and Paget Group and has an extensive background in financial services. He is involved in strategic planning, daily operations and developing the broker-dealer network for iFinix trading products.
Ricardo Brillon is the Chief Information Officer of iFinix. Mr. Brillon develops the core programming of iFinix product while project managing additional outsourced development teams, including about a dozen developers currently working full-time on iFinix products in India.
Naveen Vasudevan is the lead project manager in India who oversees the local workforce dedicated to iFinix software development and technical support.
Craig Eckert is CEO of iFinix subsidiary, R&B Computer Systems Inc. With over 20 years of technology experience and an engineering and management background, Mr. Eckert has developed strategic relationships with companies such as Ernst & Young, Accenture, Nortel, IBM, Compaq, EDS, Lucent and Goldman Sachs.
Subsidiaries and Acquisitions
R&B Consulting is presently the only iFinix subsidiary. Under Mr. Eckert's full-time guidance, R&B is currently partnering with regional and international technology consultancies as a personnel and solutions provider. Drawing on Mr. Eckert's experience, iFinix expects R&B to contribute revenues in 2007 and grow significantly in the following year.
Mr. Eckert is responsible for locating acquisition targets that would increase iFinix revenues and generate profits. Several private companies presently operating with positive cash flow are under consideration. R&B has already qualified for a Small Business Administration loan that would facilitate a contemplated acquisition in full without any need for dilution of iFinix shareholder equity.
Mr. Eckert's oversight of this separate entity ensures there will be no loss of focus on the primary financial products and services business of iFinix.
Affiliations & Partnerships
iFinix has in place all data feeds through agreements with CMA, Comtex and Pink Sheets. CMA is currently a major financial data provider to the Latin American trading markets. The iFinix and CMA association already extends beyond access to CMA exchange feeds. As iFinix grows, the synergies between the two companies may then be extended towards mutually obtaining market share in their respective North and South American markets.
Other partnerships will be explored on a regular basis as iFinix seeks to expand their products and services and increase their market reach to include all levels of retail users, professional traders, proprietary trading shops and brokerage houses. As the iFinix customer base grows, the company will explore the possibility of applying for its own broker-dealer license and thus become a fully leveraged financial services provider and brokerage house.
Corporate Governance
In positioning the company for a listing on the OTCBB exchange, iFinix has adopted policies of full disclosure and corporate transparency. 2006 annual financials are nearing completion and should be made publicly available within several weeks. At that time all itemized insider share positions, including restricted stock, will be stated. And recent corporate governance actions enacted to fully align management with shareholder interests will be disclosed.
Mr. Spadaro concludes, "iFinix is approaching critical mass as a product developer about to release a series of excellent products, as a company evolving from start-up to a serious market competitor and as a publicly traded equity that was once abandoned by the markets and is now a vital trading issue. We are gratified by the growing interest in iFinix and this management team is focused on restoring value to our shareholders by virtue of great products, hard work, ethical management practices and clean corporate governance policies."
triple bottome, MACD positive nearing 0, trend lines all converging, and RSI Wm% bullish..I would say we do have a good week coming!
Been long since Jan.....waiting for the run!
http://www.neximbank.com.ng/NEXIM%20grants%20150%20million%20Facility%20to%20support%20Sickel%20Cell....
In pursuance of its mandate of export development and facilitation as well as enhancing local raw materials utilization and employment generation, the Nigerian Export-Import Bank grants a $150 million facility to Xechem Pharmaceuticals Nigeria Ltd, a subsidiary of Xechem International ,Inc, a biopharmaceutical company based in the USA for the monthly production of five million capsules of a new Sickle Cell Drug, NICOSAN under the first phase of project Implementation at Sheda Science and Technology Complex, Abuja.
This phase of project implementation by Xechem would involve the provision of an Export Development Facility of N150 million to the company by NEXIM to facilitate the further development, commercial production and marketing of NICOSAN
On Monday, May 22nd 2006, the official signing and presentation of the N150 million cheque to Xechem Pharmaceuticals Nig, Ltd took place at the Corporate Head Office of the Bank. In attendance were the Chairman Board of Directors, NEXIM Bank, Mr. Tunde Lemo; the MD/CEO NEXIM, Alh Baba Yusuf Ahmed, the Executive Directors of the Bank- Mr. Lateef A. Balogun and Mr. Edet J. Ekere; the Chairman Xechem Pharmaceuticals Ltd Dr. Ramesh C. Pandy and other management staff of the Company; Representatives of the Federal Ministry of Science and Technology; Ministry of Health and the National Institute for Pharmaceuticals Research and Development.
In his address at the occasion, the Chairman Board of Directors, NEXIM Bank, Mr. Tunde Lemo, stated that the Bank is proud to have the opportunity to fund a scheme like that which will bring relief to many sickle cell patients around the world. He commended the National Institute for Pharmaceuticals Research and Development (NIPRD) for the invention after several years of research.
In his speech, the MD/CEO, NEXIM Bank, Alhaji Baba Yusuf Ahmed stated that the drug will go a long way to restore hope to people with the disease worldwide who for many decades had lost hope of getting any form of treatment or cure. “With over ten million sufferers in Africa, we should be able to support the cause and thereby bring hope to these people who are in need of this drug,” he said.
Responding, the Chairman of the Pharmaceutical Company, Dr. Ramesh Pandy said the drug is produced using a combination of herbs. He stated that being the first of its kind; the drug would be exported to other African countries as well as Europe and America where black people are desperately in need of it.
He explained that although the drug does not completely treat the ailment, a single dose per day helps to manage the situation thereby allowing the patient to live a normal life completely free from crisis.
The production, packaging and marketing of NICOSAN a herbal mixture produced under current Good Laboratory Practices('cGLP') and current Good Manufacturing Process('cGMP') is a novelty and a rare fact that will not only further diversify non traditional exports from Nigeria but would also bring hope and succor to over 10 million sufferers worldwide. The project has very high export potentials that would generate a yearly minimum of US$5million in foreign exchange in the first two years of operations from Royalty payments and product shipments.
The disbursement of the Export Development Facility to the Company by NEXIM also has some socioeconomic benefits, such as the creation of employment opportunities to about 80 Nigerians, largely Scientists and Researchers and a market opportunity for Nigerian farmers to annually supply over 720 tonnes of raw materials for the project.
QMMG nice play down here..lots of upside potential
http://stockcharts.com/charts/gallery.html?QMMG
up 8% and filling the gap
this is a nice play down here...lots of upside potential
filling the gap
http://gsa.confex.com/gsa/2007RM/finalprogram/abstract_119785.htm
Presentation Time: 8:10 AM-8:30 AM
URANIUM IN UTAH
KRAHULEC, Ken, Energy and Minerals, Utah Geological Survey, P.O. Box 146100, Salt Lake, UT 84114, kenkrahulec@utah.gov
Utah is the third-largest uranium producing state in the U.S. with a cumulative production of some 130 million pounds of U3O8. Although all Utah uranium production has ceased, Utah still has two of the four currently permitted uranium mills in the U.S.: the operating dual-circuit White Mesa U-V mill near Blanding and the Shootaring U mill at Ticaboo, which is on standby.
The vast majority of Utah's uranium production has come from small, low- to moderate-grade, sandstone-hosted uranium deposits mined underground in the Colorado Plateau, although there has also been minor production from volcanic and volcaniclastic rocks in western Utah. The sandstone-hosted uranium ore bodies are peneconcordant, both tabular and roll front, and typically occur in linear clusters along favorable channels and trends. The Lisbon Valley (Big Indian) mining district is Utah's largest uranium district with nearly 54 million pounds of U3O8 produced. Unmined uranium mineral resources remain at many old Utah properties with the largest known resource being the roughly 20 million pounds of U3O8 remaining at the Bullfrog-Tony M deposits in the Shootaring-Delmonte district of the southern Henry Mountains. Most of the current exploration and development work in Utah is focused on the Lisbon Valley, La Sal, La Sal Creek, and Henry Mountains areas.
The principal sedimentary ore hosts in Utah are fluvial-lacustrine sandstones of the (1) Triassic Chinle Formation, yielding roughly 80% of the uranium ore, (2) the Jurassic Morrison Formation, the leading vanadium producer, and (3) lesser production from the Permian Cutler Formation. The main ore producers in the Chinle Formation are the basal Shinarump Member, which is coarse-grained sandstone, and the Moss Back Member, which is typically cross-bedded, medium-grained sandstone. Whichever of these members is in contact with the underlying Moenkopi Formation is typically the primary ore host in the Chinle Formation. The basal Salt Wash Member is the primary ore host in the Morrison Formation. The Salt Wash Member is fine- to medium-grained, cross-bedded sandstone. The Cutler Formation is a much less important uranium host and is arkosic sandstone where the mineralization is typically uranium-copper.
something is up...lots of buys...
Looks like the mmS and flippers killed the pps, but there is some serious volume action going on here again..something is up..I would say it is a good time to get in now again.
KMO
the uptick has already begun...
http://www.stocktargets.com/cgi-bin/ticker.pl?command=chnw.pk
Now wouldn't that be nice?
Great close...gap up monday. GLTA
If there is no wick or a very small one this is going to gap up hard on Monday.
KMO
And I was just looking to make a quick 20%...WTF was I thinking???
Nice! We are going to definately see a gap up on Monday.
Ask .0031
Ask @ .003!
Doms at .0033...
Wee We Go!
I saw that..NICE!
I see very strong buys coming in nailing the ask
What's up with NAWL...any thoughts?
From their news yesterday, I imagine a continuation throught the weekend or by the EOD. It appears that gap is being filled from yesterday's wick, and the last 1/2 hour I saw some heavy buys coming in a t the .002 level. What do you all think?
http://en.wikipedia.org/wiki/NASDAQ
And some sites to help you along...
CHARTS:
http://www.incrediblecharts.com/technical/easy_guide.htm
http://portals2.wallstreettape.com:8081/charts/custom/charts.asp?t=HL,cs[d],cp[d],ct[c],csc[l],cv[o]....
http://www.elliottwavesignals.com/outlook/index.htm
http://www.stockcharts.com
http://www.litwick.com/glossary.html
http://www.chartpatterns.com/
http://www.candlestickshop.com/glossary/
http://www.stockta.com
SCREENERS:
http://screen.morningstar.com/StockSelector.html
http://www.stockfetcher.com
http://screener.finance.yahoo.com/newscreener.html
http://smallcapcenter.com/tools_tools.asp
PRESS RELEASE:
http://home.businesswire.com/portal/site/home/index.jsp?front_door=true
GENERAL INFORMATIONS :
http://www.thestreet.com/tech/index.html?s=left
http://www2.barchart.com
http://www.smallcapcenter.com
http://www.cboe.com/Home/Default.asp
http://finance.yahoo.com/?u
http://www.quotetracker.com/
http://cbs.marketwatch.com/news/default.asp?siteid=&avatar=seen
http://nasdaq.com/
http://clearstation.etrade.com/cgi-bin/events?Cmd=techev
http://www.otcbb.com/asp/default.asp
http://www.americanbulls.com
http://moneycentral.msn.com/investor/market/top10industries.asp
SEC FILINGS:
http://www.edgar-online.com/
http://www.sec.gov/
http://www.pinksheets.com
NASDAQ quotes are available at three levels. Level I shows the highest bid and lowest offer — the inside quote. Level II shows all public quotes of market makers together with information of market makers wishing to sell or buy stock and recently executed orders. Level III is used by the market makers and allows them to enter their quotes and execute orders.
as well. Didi you see those 5000 mirror trades of buys in at .0019?
http://stockcharts.com/charts/gallery.html?NAWL
This is going up - easy double KMO
L2 is set up nicely for a formidable gain. Hangman doji formed followed by White Marbuzu last trade blocks. Buys are coming in...